arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Immuneering Corporation

IMRX Health Care Biotechnology: Pharmaceutical Preparations
$3.73
▼ -0.3% Today
as of Oct 23, 16:49 ET
Last 30 days -13.86% Sep 14 → Oct 23
$3.32 $3.67 $4.02 $4.36 $4.71 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$3.78
High
$3.78
Low
$3.58
Volume
$726,259
Avg Vol
$1M
Mkt Cap
$261M
P/E (TTM)
—
Beta
—
52w High
$8.48
52w Low
$3.38
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 6 items

Oct 2 · 13:00 PR GlobeNewswire
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Sep 28 · 11:30 PR GlobeNewswire
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
Sep 24 · 11:30 PR GlobeNewswire
Immuneering to Present at the ESMO Congress 2026
▸ Show all 6 press releases & news Free account →

IMRX earnings at a glance

The options market is pricing a move of about ±62.5% after the report, a range of roughly $1.40 to $6.06 from today's $3.73. Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±0.6% on average; after the most recent report on May 15, 2026 it moved +0.4%. That means options currently expect more movement than IMRX has typically delivered. IMRX beat the consensus EPS estimate in 1 of its last 4 reported quarters. Implied volatility is currently 5%. The share price of $3.73 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$3.38
$8.48
7% of range
Avg surprise (last 4)
+6.2%
Avg reaction (last 2)
+0.6%
100% positive
Latest IV / EM
529%
EM ±62.5% · $5 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.51$-0.43$-0.36$-0.28$-0.21 Actual $-0.51Actual $-0.43Actual $-0.43Actual $-0.49Actual $-0.47Actual $-0.49Actual $-0.42Est $-0.41Actual $-0.40Est $-0.40Actual $-0.38Est $-0.37Actual $-0.21Est $-0.30Actual $-0.27 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-17M$-16M$-16M$-15M$-14M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.27 — — — — financials
Fri May 15, 2026Mar/2026 $-0.21 $-0.30 +30.0% +50.0% +0.4% earnings
Wed Nov 12, 2025Sep/2025 $-0.38 $-0.37 -2.7% — — earnings
Wed Aug 13, 2025Jun/2025 $-0.40 $-0.40 0.0% — — earnings
Mon May 5, 2025Mar/2025 $-0.42 $-0.41 -2.4% — +0.8% earnings
Mon Sep 30, 2024Sep 2024 $-0.49 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.47 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.49 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.43 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.43 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.51 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-19M$-15M—$-15M$-15M$-15M—$-15M
Net income$-17M$-13M—$-15M$-14M$-15M—$-15M
EPS (diluted)$-0.27$-0.21—$-0.38$-0.40$-0.42—$-0.49

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$41M$47M$129M$228M$26M$36M$36M$45M
Inventory————————
Total current assets$158M$161M$176M$229M$28M$38M$40M$55M
Total assets$202M$215M$232M$241M$40M$51M$53M$69M
Long-term debt————————
Total liabilities$11M$8M$14M$13M$11M$9M$11M$11M
Total equity$191M$207M$218M$228M$29M$42M$41M$58M

Implied volatility — last 90 days

33%199%365%531%697% Jun 07 — IV 110% · EM ±15.2%Jun 08 — IV 568% · EM ±75.0%Jun 09 — IV 406% · EM ±50.9%Jun 10 — IV 475% · EM ±56.1%Jun 11 — IV 402% · EM ±44.4%Jun 12 — IV 408% · EM ±41.8%Jun 15 — IV 531% · EM ±38.4%Jun 16 — IV 503% · EM ±29.7%Jun 17 — IV 570% · EM ±23.8%Jun 19 — IV 113% · EM ±24.9%Jun 22 — IV 101% · EM ±21.2%Jun 23 — IV 132% · EM ±27.0%Jun 24 — IV 86% · EM ±17.3%Jun 25 — IV 87% · EM ±17.1%Jun 26 — IV 91% · EM ±17.4%Jun 29 — IV 75% · EM ±13.4%Jun 30 — IV 81% · EM ±14.0%Jul 01 — IV 86% · EM ±14.4%Jul 02 — IV 113% · EM ±18.3%Jul 03 — IV 117% · EM ±18.3%Jul 06 — IV 98% · EM ±13.6%Jul 07 — IV 78% · EM ±10.3%Jul 08 — IV 105% · EM ±13.1%Jul 09 — IV 107% · EM ±12.6%Jul 10 — IV 94% · EM ±10.4%Jul 13 — IV 75% · EM ±6.3%Jul 14 — IV 113% · EM ±8.2%Jul 15 — IV 139% · EM ±8.2%Jul 16 — IV 250% · EM ±10.4%Jul 20 — IV 187% · EM ±44.3%Jul 21 — IV 102% · EM ±23.8%Jul 22 — IV 132% · EM ±30.2%Jul 23 — IV 152% · EM ±34.2%Jul 24 — IV 107% · EM ±23.6%Jul 27 — IV 99% · EM ±20.6%Jul 28 — IV 92% · EM ±18.9%Jul 29 — IV 240% · EM ±48.1%Jul 30 — IV 113% · EM ±22.1%Jul 31 — IV 209% · EM ±40.0%Aug 03 — IV 237% · EM ±42.0%Aug 04 — IV 33% · EM ±5.7%Aug 05 — IV 123% · EM ±20.5%Aug 06 — IV 250% · EM ±40.4%Aug 10 — IV 191% · EM ±26.5%Aug 11 — IV 99% · EM ±13.0%Aug 12 — IV 71% · EM ±8.9%Aug 13 — IV 126% · EM ±14.9%Aug 14 — IV 107% · EM ±11.9%Aug 17 — IV 344% · EM ±28.7%Aug 19 — IV 286% · EM ±16.9%Aug 20 — IV 365% · EM ±15.2%Aug 24 — IV 83% · EM ±17.4%Aug 25 — IV 72% · EM ±14.8%Aug 26 — IV 70% · EM ±14.1%Aug 27 — IV 64% · EM ±12.5%Aug 28 — IV 75% · EM ±14.4%Aug 31 — IV 68% · EM ±12.0%Sep 01 — IV 60% · EM ±10.3%Sep 02 — IV 65% · EM ±10.8%Sep 03 — IV 55% · EM ±8.9%Sep 04 — IV 46% · EM ±7.3%Sep 07 — IV 52% · EM ±7.3%Sep 08 — IV 127% · EM ±16.7%Sep 09 — IV 95% · EM ±11.9%Sep 10 — IV 116% · EM ±13.7%Sep 11 — IV 201% · EM ±22.2%Sep 14 — IV 263% · EM ±21.9%Sep 15 — IV 342% · EM ±24.8%Sep 16 — IV 400% · EM ±23.6%Sep 17 — IV 698% · EM ±29.1%Sep 21 — IV 178% · EM ±37.2%Sep 22 — IV 87% · EM ±17.9%Sep 23 — IV 142% · EM ±28.5%Sep 24 — IV 124% · EM ±24.2%Sep 25 — IV 107% · EM ±20.5%Sep 28 — IV 190% · EM ±33.7%Sep 29 — IV 162% · EM ±27.8%Sep 30 — IV 234% · EM ±39.1%Oct 01 — IV 199% · EM ±32.3%Oct 02 — IV 220% · EM ±34.4%Oct 06 — IV 445% · EM ±58.7%Oct 07 — IV 486% · EM ±60.9%Oct 08 — IV 529% · EM ±62.5%

Sector peers

BCYC
Bicycle Therapeutics plc
$261M $3.55-0.6%
AMRN
Amarin Corporation plc
$254M $11.79+2.4%
IFRX
InflaRx N.V.
$252M $1.56+0.7%
QTTB
Q32 Bio Inc.
$246M $8.65-0.2%
AKBA
Akebia Therapeutics, Inc.
$241M $0.57-3.1%
INDP
Indaptus Therapeutics, Inc.
$282M $3.160.0%

IMRX earnings FAQ

What is IMRX's expected move for earnings?

Options currently price a move of about ±62.5%, or $2.33 per share either way from $3.73.

How does IMRX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±0.6%, up 2 times and down 0 times.

What is IMRX's implied volatility?

IMRX's at-the-money implied volatility is about 5% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in